Stock LLY0 ELI LILLY AND COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Eli Lilly and Company Deutsche Boerse AG

Equities

LLY0

CA28655A1066

Delayed Deutsche Boerse AG
Other stock markets
 06:59:01 27/06/2024 pm IST 		5-day change 1st Jan Change
22 EUR 0.00% Intraday chart for Eli Lilly and Company +0.92% 0.00%
26/06 Augustine Therapeutics N.V. announced that it expects to receive funding from a group of investors CI
25/06 Top Midday Stories: Microsoft Hit with EU Antitrust Charges; Judge Blocks Swipe-Fee Settlement Between Visa, Mastercard and Retailers; Novo Nordisk Secures Chinese Approval for Weight-Loss Drug; Tesla, Ford Issue Recalls MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's profit outlook over the next few years is a strong asset.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Analyst opinion has improved significantly over the past four months.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 67.41 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ELI LILLY AND COMPANY Stock Eli Lilly and Company
0.00% 811B -
NOVO NORDISK A/S Stock Novo Nordisk A/S
+43.73% 640B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.48% 353B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.26% 333B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.68% 302B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.34% 246B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.49% 225B
A+
NOVARTIS AG Stock Novartis AG
+12.81% 218B
B-
AMGEN INC. Stock Amgen Inc.
+9.18% 168B
C+
PFIZER, INC. Stock Pfizer, Inc.
-5.94% 155B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. LLY0 Stock
  5. Ratings Eli Lilly and Company